Axicabtagene ciloleucel (axi-cel) appears to be both safe and effective for treating relapsed/refractory follicular lymphoma (FL), according to research presented at the European Hematology Association (EHA) 2021 Virtual Congress.
The phase 2 ZUMA-5 trial (ClinicalTrials.gov Identifier: NCT03105336) previously demonstrated that axi-cel, a chimeric antigen receptor (CAR)-T cell therapy targeting CD19, showed a both high overall response rate and long duration of response in patients with relapsed/refractory FL, including in patients with high-risk disease.
In this presentation, the authors reported comparative clinical outcomes from updated ZUMA-5 data and the international SCHOLAR-5 cohort.
Data from the SCHOLAR-5 cohort were taken from 7 institutions, and included data from a previous trial of idelalisib; patients in SCHOLAR-5 had received a third-line or later therapy after July 2014. Patient characteristics were balanced between the ZUMA-5 and SCHOLAR-5 cohorts.
Overall, data from 86 patients in ZUMA-5 and 85 patients in SCHOLAR-5 were included; the median follow-up times were 23.3 months and 26.2 months, respectively. Patients in the SCHOLAR-5 cohort had more patients with an Eastern Cooperative Oncology Group score of 1 at baseline, despite attempts to match characteristics.
In patients who had received at least 2 prior therapy lines, the overall response rates were 49.9% in SCHOLAR-5 vs 94.2% in ZUMA-5 (odds ratio, 16.2; 95% CI, 5.6-46.9). The median progression-free survival and overall survival periods were not reached in ZUMA-5, and were 12.7 months and 59.8 months, respectively, in SCHOLAR-5; the corresponding hazard ratios for progression-free and overall survival were 0.30 (95% CI, 0.18-0.49) and 0.42 (95% CI, 0.21-0.83), respectively.
“These data support that axi-cel represents a significant improvement in treatment options for patients with relapsed/refractory FL,” the presenter said.
Disclosure: The presenter declared affiliations with AstraZeneca, Kite, A Gilead Company, Gilead, Abbvie, Bristol Myers Squibb, MorphoSys, Novartis, Takeda, TG Therapeutics, Janssen.
Ghione P, Anik Patel A, Bobillo S, et al. A comparison of clinical outcomes from ZUMA-5 (axicabtagene ciloleucel) and the international SCHOLAR-5 external control cohort in relapsed/refractory follicular lymphoma (R/R FL). Paper presented at: European Hematology Association 2021 Virtual Congress; June 2021; Abstract LB1904.
The post Relapsed, Refractory Follicular Lymphoma: CAR-T Cell Therapy Shows Promise appeared first on Cancer Therapy Advisor.
more recommended stories
Ardena’s Expertise Helps New Treatment for Parkinson’s Disease
Ghent, Belgium 30 August 2021: Ardena,.
The Fight for Air Climb and Other Extraordinary Feats by People With PF
A couple of weeks ago, Bert.
Inflatable Neurostimulator for Minimally Invasive Pain Control
Researchers at the University of Cambridge.
Glucagon-like Peptide-1 Metabolism is Impacted by Anthocyanins and (-)-epicatechin
Obesity and diabetes are major health.
The Last Mile: Overcoming COVID-19 Vaccine Hesitancy
Special thanks to Marc Benjamin, a.
The latest science on staying healthy during pregnancy
New research examines prenatal supplements, how.
Living With PTSD? How to Manage Anxiety and Flashbacks
If you have post-traumatic stress disorder (PTSD), you.
Strategic Partnership Announced Between IDBS and Scitara
Biopharmaceutical lifecycle management platform IDBS (Guildford,.
DLBCL: Naratuximab Shows Promise Among Patients With Relapsed/Refractory Disease
Among patients with diffuse large B.
Quasiprobabilities Shed Light on Quantum Advantage
Quantum advantage is a hot topic,.